cvs pharmacy meridianville al
Topline:
Nebulized amphotericin B does not improve exacerbation-free status at 1 year for patients with bronchopulmonary aspergillosis, though it may delay onset and incidence.
Methodology:
-
Investigators searched PubMed and Embase databases for studies that included at least five patients with allergic bronchopulmonary aspergillosis who were managed with nebulized amphotericin B.
-
They included five studies, two of which were randomized controlled trials (RCTs), and three were observational studies; there was a total of 188 patients.
-
The primary objective of this systematic review and meta-analysis was to determine the frequency of patients remaining exacerbation free 1 year after initiating treatment with nebulized amphotericin B.
Takeaway:
-
From the studies (one observational, two RCTs; n = 84) with exacerbation data at 1 or 2 years, the pooled proportion of patients who remained exacerbation free with nebulized amphotericin B at 1 year was 76% (I2 = 64.6%).
-
The pooled difference in risk with the two RCTs that assessed exacerbation-free status at 1 year was 0.33 and was not significantly different between the nebulized amphotericin B and control arms, which received nebulized saline.
-
Two RCTs provided the time to first exacerbation, which was significantly longer with nebulized amphotericin B than with nebulized saline (337 vs 177 days; P = .004; I2 = 82%).
-
The proportion of patients who experienced two or more exacerbations was significantly lower with nebulized amphotericin B than with nebulized saline (9/33 [27.3%] vs 20/38 [52.6%]; P = .03).
In Practice:
“The time to first exacerbation was prolonged with NAB [nebulized amphotericin B]therapy and is an important indicator of effectiveness. Also, the proportion of subjects experiencing ≥2 exacerbation was also lesser with NAB than in the control, cipro antibiotico infecção urinaria ” concluded Valliappan Muthu, MD, and colleagues. However, “the ideal duration and optimal dose of LAMB for nebulization are unclear.”
Study Details
“Nebulized Amphotericin B for Preventing Exacerbations in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis” was published online in Pulmonary Pharmacology and Therapeutics in May 2023.
Limitations
The current review is limited by the small number of included trials and may have a high risk of bias. Therefore, more evidence is required for the use of nebulized amphotericin B in routine care. The authors have disclosed no conflicts of interest.
For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.
Source: Read Full Article